167 related articles for article (PubMed ID: 28599406)
1. Ocoxin oral solution
Hernandez-Unzueta I; Benedicto A; Olaso E; Sanz E; Viera C; Arteta B; Márquez J
Oncol Lett; 2017 Jun; 13(6):4002-4012. PubMed ID: 28599406
[TBL] [Abstract][Full Text] [Related]
2. Ocoxin® oral solution slows down tumor growth in an experimental model of colorectal cancer metastasis to the liver in Balb/c mice.
Márquez J; Mena J; Hernandez-Unzueta I; Benedicto A; Sanz E; Arteta B; Olaso E
Oncol Rep; 2016 Mar; 35(3):1265-72. PubMed ID: 26676882
[TBL] [Abstract][Full Text] [Related]
3. Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer.
Díaz-Rodríguez E; Sanz E; Pandiella A
Int J Oncol; 2018 Jul; 53(1):113-123. PubMed ID: 29658597
[TBL] [Abstract][Full Text] [Related]
4. Antitumoral effect of Ocoxin in hepatocellular carcinoma.
Díaz-Rodríguez E; El-Mallah AM; Sanz E; Pandiella A
Oncol Lett; 2017 Aug; 14(2):1950-1958. PubMed ID: 28781639
[TBL] [Abstract][Full Text] [Related]
5. Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin.
Pérez-Peña J; Díaz-Rodríguez E; Sanz E; Pandiella A
Nutrients; 2019 May; 11(5):. PubMed ID: 31091680
[TBL] [Abstract][Full Text] [Related]
6. Ocoxin oral solution demonstrates antiviral properties in cellular models.
Pandiella A; Sanz E; Díaz-Rodríguez E
Exp Ther Med; 2021 Oct; 22(4):1127. PubMed ID: 34504579
[TBL] [Abstract][Full Text] [Related]
7. Antitumoral Properties of the Nutritional Supplement Ocoxin Oral Solution: A Comprehensive Review.
Pandiella-Alonso A; Díaz-Rodríguez E; Sanz E
Nutrients; 2020 Aug; 12(9):. PubMed ID: 32878230
[TBL] [Abstract][Full Text] [Related]
8. Antitumoral effect of Ocoxin on acute myeloid leukemia.
Díaz-Rodríguez E; Hernández-García S; Sanz E; Pandiella A
Oncotarget; 2016 Feb; 7(5):6231-42. PubMed ID: 26756220
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
10. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Varol U; Karaca B; Cakar B; Sezgin C; Karabulut B; Uslu R
Am J Clin Oncol; 2013 Aug; 36(4):388-91. PubMed ID: 22643568
[TBL] [Abstract][Full Text] [Related]
11. Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma.
Hernández-SanMiguel E; Gargini R; Cejalvo T; Segura-Collar B; Núñez-Hervada P; Hortigüela R; Sepúlveda-Sánchez JM; Hernández-Laín A; Pérez-Núñez A; Sanz E; Sánchez-Gómez P
Oxid Med Cell Longev; 2019; 2019():9719730. PubMed ID: 31467641
[TBL] [Abstract][Full Text] [Related]
12. Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.
Maki H; Hojo K; Tanaka H; Sawada TY; Maekawa R; Yoshioka T
Clin Exp Metastasis; 2002; 19(6):519-26. PubMed ID: 12405289
[TBL] [Abstract][Full Text] [Related]
13. Ocoxin as a complement to first line treatments in cancer.
Benedicto A; Sanz E; Márquez J
Int J Med Sci; 2021; 18(3):835-845. PubMed ID: 33437220
[TBL] [Abstract][Full Text] [Related]
14. Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer.
Hernández-García S; González V; Sanz E; Pandiella A
Nutr Cancer; 2015; 67(7):1159-69. PubMed ID: 26241555
[TBL] [Abstract][Full Text] [Related]
15. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J; Rodriguez-Remirez M; Borrero-Palacios A; Moreno I; Cebrian A; Gomez del Pulgar T; del Puerto-Nevado L; Vega-Bravo R; Puime-Otin A; Perez N; Zazo S; Senin C; Fernandez-Aceñero MJ; Soengas MS; Rojo F; Garcia-Foncillas J
BMC Cancer; 2014 Dec; 14():965. PubMed ID: 25515240
[TBL] [Abstract][Full Text] [Related]
16. Current treatments and future perspectives in colorectal and gastric cancer.
Wilke HJ; Van Cutsem E
Ann Oncol; 2003; 14 Suppl 2():ii49-55. PubMed ID: 12810459
[TBL] [Abstract][Full Text] [Related]
17. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
18. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
[TBL] [Abstract][Full Text] [Related]
19. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
20. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
